KRYS - Company ID 0001711279
Krystal Biotech, Inc. trades as KRYS and has a market capitalization of $10.83 B, making it the #911 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $389.13M, up 33.9% from the prior year and net income of $204.83M. This page tracks Krystal Biotech, Inc. through 483 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from 21.6% to 52.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Major company event | 8-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-04 |
| Quarterly report | 10-Q | 2026-05-04 |
| SCHEDULE 13G/A | - | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-03 |
| Proxy materials | DEFA14A | 2026-04-03 |
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | Krystal Biotech, Inc.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference | Krystal Biotech, Inc.
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results | Krystal Biotech, Inc.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916 .
Krystal Biotech to Present at Upcoming Scientific Conferences | Krystal Biotech, Inc.
The largest companies sharing Krystal Biotech, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Krystal Biotech, Inc. (KRYS) has a market capitalization of $10.83 B as of 2026-07-09, ranking #911 among US-listed companies.
Krystal Biotech, Inc. reported revenue of $389.13M for fiscal year 2025, an increase of 33.9% year over year.
Yes. Krystal Biotech, Inc. reported net income of $204.83M in its latest fiscal year.